Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.50 |
| ▸ | FEN1 | P39748 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.40 |
| ▸ | KIF11 | P52732 | 2/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5175215 | 0.84 | ALOX5AP (0.44) | ALOX5APFEN1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL7449404 | 0.79 | ALOX5AP (0.42) | ALOX5APFEN1TDP1ALDH1A1KDM4E | |
| SCHEMBL1270076 | 0.78 | CYP3A4 (0.48) | ALOX5APFEN1TDP1ALDH1A1KDM4E | |
| SCHEMBL4250948 | 0.76 | ALDH1A1 (0.41) | ALOX5APFEN1TDP1ALDH1A1KDM4E | |
| SCHEMBL2785165 | 0.75 | ALOX5AP (0.46) | ALOX5APFEN1TDP1ALDH1A1KDM4E | |
| SCHEMBL27993955 | 0.73 | CYP3A4 (0.43) | TDP1ALDH1A1KDM4ECYP3A4HSD17B10 | |
| SCHEMBL9246341 | 0.72 | HSD17B10 (0.63) | TDP1ALDH1A1KDM4ECYP3A4HSD17B10 | |
| SCHEMBL3787013 | 0.72 | CYP3A4 (0.46) | ALOX5APFEN1TDP1ALDH1A1KDM4E | |
| SCHEMBL29549836 | 0.71 | MAPT (0.54) | ALOX5APFEN1TDP1ALDH1A1KDM4E | |
| SCHEMBL398169 | 0.71 | MAPT (0.54) | ALOX5APFEN1TDP1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962935-B2 | Oxygen or sulfur containing heteroaromatics as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| US-20040073029-A1 | Oxygen or sulfur containing heteroaromatics as factor Xa inhibitors | PRUITT JAMES RUSSELL (US) | 2004-04-15 | — | — | US | disclosed |
| US-6569874-B1 | Such as 2-acetylamino-4-(3-amidinophenyl)-5-((2'-amino-sulfonyl-(1,1')-biphen-4 -yl)aminocarbonyl)thiazole; for treatment of thromboembolic disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-05-27 | — | — | US | disclosed |
| EP-0946528-B1 | OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6187797-B1 | ANTICOAGULANTS; TRYPSINE-LIKE SERINE PROTEASE INHIBITORS | DUPONT PHARMACEUTICALS COMPANY | 2001-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073029-A1 | Oxygen or sulfur containing heteroaromatics as factor Xa inhibitors | F12, XDH, F2 | ALOX5AP 2392/4885FEN1 1513/4885TDP1 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.